Work

A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-147567

Authors: Mark Roschewski, Veerendra Munugalavadla, Barrett Nuttall, Kathleen Burke, Melih Acar, Rafael White, Maria Udriste, Shringi Sharma, Brian Dougherty, Ian Flinn, Nakhle S. Saba, Patrick M. Reagan, Sven de Vos, Hendrik-Tobias Arkenau, Graham P. Collins, Andrew Mortlock, Manish R. Patel

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, AstraZeneca (United States), AstraZeneca (United Kingdom), Sarah Cannon, Tulane Medical Center, University of Rochester Medicine, University of Rochester, University of California, Los Angeles, Sarah Cannon Research Institute, University College London, Churchill Hospital, NIHR Oxford Biomedical Research Centre, Florida Cancer Specialists & Research Institute

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3212748355

Cites:

Cited by: 3

Related to: 10